Real-World Data and Real-World Evidence in Hematologic Malignancies

57K

views

196

authors

21

articles

Real-World Data and Real-World Evidence in Hematologic Malignancies

57K

views

196

authors

21

articles

Editorial

09 June 2023

Editorial: Real-world data and real-world evidence in hematologic malignancies

Michele Malagola

,

Robert Ohgami

and

Raffaella Greco

1,733 views

0 citations

Editors

3

Michele Malagola

University of Brescia

The University of Utah

Raffaella Greco

San Raffaele Hospital (IRCCS)

Impact

Fetching...

About

Whilst clinical trials are often considered to be the most accurate source of data regarding the efficacy of treatments, results seen in the real-world setting often differ significantly. Disparities in accrual rates amongst different ethnic and socio-economic groups, as well as strict enrollment criteria which exclude certain patient populations from trials, contribute to differences in outcomes observed between patients treated in clinical trials and in the real-world setting. Increasingly, these differences are being recognized, and as such, more attention is being given to real-world data (RWD) and real-world evidence (RWE) in the field of hematologic malignancies.

RWD and RWE can be used to address gaps in knowledge gained from clinical trials, detect rare events, inform safety labeling, and identify patient subgroups who are more or less likely to benefit from certain therapies, ultimately helping healthcare professionals to optimize treatment decisions. RWD and RWE can also provide insights into patterns of care and in different geographic and economic scenarios.

This collection aims to collate studies assessing RWD and RWE which can be used to inform the treatment of hematologic malignancies in clinical practice. This collection will accept manuscripts on, but not limited to, the following research areas:
- RWD or RWE studies describing treatment efficacy in patients with hematologic malignancies
- RWD or RWE in rare/orphan subtypes of hematologic malignancies
- RWD or RWE studies describing the safety and long-term adverse events of treatment in patients with hematologic malignancies

Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Whilst clinical trials are often considered to be the most accurate source of data regarding the efficacy of treatments, results seen in the real-world setting often differ significantly. Disparities in accrual rates amongst different ethnic and socio-economic groups, as well as strict enrollment criteria which exclude certain patient populations from trials, contribute to differences in outcomes observed between patients treated in clinical trials and in the real-world setting. Increasingly, these differences are being recognized, and as such, more attention is being given to real-world data (RWD) and real-world evidence (RWE) in the field of hematologic malignancies.

RWD and RWE can be used to address gaps in knowledge gained from clinical trials, detect rare events, inform safety labeling, and identify patient subgroups who are more or less likely to benefit from certain therapies, ultimately helping healthcare professionals to optimize treatment decisions. RWD and RWE can also provide insights into patterns of care and in different geographic and economic scenarios.

This collection aims to collate studies assessing RWD and RWE which can be used to inform the treatment of hematologic malignancies in clinical practice. This collection will accept manuscripts on, but not limited to, the following research areas:
- RWD or RWE studies describing treatment efficacy in patients with hematologic malignancies
- RWD or RWE in rare/orphan subtypes of hematologic malignancies
- RWD or RWE studies describing the safety and long-term adverse events of treatment in patients with hematologic malignancies

Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Download ebook

Share

Editors

Michele Malagola

University of Brescia

The University of Utah

Raffaella Greco

San Raffaele Hospital (IRCCS)

Impact

57,047 Total views

38,321 Article views

18,104 Article downloads

622 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Hematologic Malignancies

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic